A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)
Study of CPI-0610 in Patients with Myelofibrosis
Sponsor: Constellation Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAR8502
U.S. Govt. ID: NCT02158858
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: We are doing this study to find out if an investigational drug called CPI-0610 can help with myelofibrosis. An investigational drug is a drug that is not approved for sale in the United States by the Food and Drug Administration (FDA). This study has two groups (arms) one group of patients will be treated with CPI-0610 alone (monotherapy arm) and the other group of patients will be treated with CPI-0610 in combination with ruxolitinib (combination arm).
This study is closed
Mark Heaney, MD, PhD
Do You Qualify?
Are you 18 years or older? Yes No
Do you have myelofibrosis (MF)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator